person · Reporting owner

SZOSTAK M ANNE

Disclosed activity across 3 companies

Tapewire entity: 48493
SEC CIK: 0001094176

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
IDEXX LABORATORIES INC /DEIDXX · Entity 3057	Director	May 07, 2026	May 11, 2026
TUPPERWARE BRANDS CORPTUP · Entity 90566	Director	May 06, 2022	May 10, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

IDEXX LABORATORIES INC /DE

Report date May 07, 2026 · Filed May 11, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	519	Reported balance After 2026-05-07 transaction · row 1 1 source row Row 1 · 2026-05-07 · Exercise / conversion · Acquired 257 · Balance 519
Restricted Stock UnitSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-05-07 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-05-07 · Exercise / conversion · Disposed 257 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock that vested in one installment on May 7, 2026. F4: Not applicable.
Common StockSEC Table I · non-derivative	IndirectTrust of M. Anne Szostak	1,542	Reported balance Holding disclosure · report date 2026-05-07 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 1,542 F1: The reporting person is the settlor of the Trust of M. Anne Szostak ("Trust") and the trustee of the Trust, has power to direct the distribution of Trust assets, and has the power to revoke or amend the Trust. The reporting person has a pecuniary interest in the shares held by the Trust.
Common StockSEC Table I · non-derivative	IndirectThe O'Hanian-Szostak Family Foundation	259	Reported balance Holding disclosure · report date 2026-05-07 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 259 F2: The reporting person is a trustee of The O'Hanian-Szostak Family Foundation ('Foundation') and has power to direct the distribution of assets held by the Foundation.

Filing footnotes · ownership attribution and instrument terms

F1: The reporting person is the settlor of the Trust of M. Anne Szostak ("Trust") and the trustee of the Trust, has power to direct the distribution of Trust assets, and has the power to revoke or amend the Trust. The reporting person has a pecuniary interest in the shares held by the Trust.

F2: The reporting person is a trustee of The O'Hanian-Szostak Family Foundation ('Foundation') and has power to direct the distribution of assets held by the Foundation.

F3: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock that vested in one installment on May 7, 2026.

F4: Not applicable.

TUPPERWARE BRANDS CORP

Report date May 06, 2022 · Filed May 10, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	88,858	Reported balance After 2022-05-06 transaction · row 1 1 source row Row 1 · 2022-05-06 · Grant · Acquired 15,106 · Balance 88,858 F1: Restricted Stock Unit award that vests on the Issuer's next Annual Meeting of Shareholders, currently planned for May 5, 2023, at which time the units convert into Tupperware Brands' Corporation common stock on a one-for-one basis.

Filing footnotes · ownership attribution and instrument terms

F1: Restricted Stock Unit award that vests on the Issuer's next Annual Meeting of Shareholders, currently planned for May 5, 2023, at which time the units convert into Tupperware Brands' Corporation common stock on a one-for-one basis.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Keurig Dr Pepper Inc.

Report date July 09, 2018 · Filed July 10, 2018

Section 16 reporting ended · disclosed 2018-07-10. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	5,095	Ending reported balance After 2018-07-09 transaction · row 6 6 source rows · reconciled sequence Row 1 · 2018-07-09 · Exercise / conversion · Acquired 1,685 · Balance 1,685 F1: Pursuant to the Agreement and Plan of Merger, dated as of January 29, 2018, (the "Merger Agreement"), by and among Maple Parent Holdings Corp., a Delaware corporation ("Maple Parent"), DPS and Salt Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of DPS ("Merger Sub"), Merger Sub merged on July 9, 2018 with and into Maple Parent (the "Merger"), with Maple Parent surviving the Merger as a wholly-owned subsidiary of DPS. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Restricted Stock Unit ("RSU") of DPS will be settled in exchange for (i) a number of shares underlying such DPS RSU, and (ii) an amount in cash equal to the number of shares underlying such DPS RSU multiplied by the special cash dividend per share amount. Row 2 · 2018-07-09 · Other · Acquired 91 · Balance 1,776 F2: These shares are restricted stock units acquired with dividend equivalent payments made under the Issuer's dividend reinvestment plan with respect to the shares referenced in row (1) above. Row 3 · 2018-07-09 · Exercise / conversion · Acquired 1,796 · Balance 3,572 F1: Pursuant to the Agreement and Plan of Merger, dated as of January 29, 2018, (the "Merger Agreement"), by and among Maple Parent Holdings Corp., a Delaware corporation ("Maple Parent"), DPS and Salt Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of DPS ("Merger Sub"), Merger Sub merged on July 9, 2018 with and into Maple Parent (the "Merger"), with Maple Parent surviving the Merger as a wholly-owned subsidiary of DPS. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Restricted Stock Unit ("RSU") of DPS will be settled in exchange for (i) a number of shares underlying such DPS RSU, and (ii) an amount in cash equal to the number of shares underlying such DPS RSU multiplied by the special cash dividend per share amount. Row 4 · 2018-07-09 · Other · Acquired 54 · Balance 3,626 F3: These shares are restricted stock units acquired with dividend equivalent payments made under the Issuer's dividend reinvestment plan with respect to the shares referenced in row (3) above. Row 5 · 2018-07-09 · Exercise / conversion · Acquired 1,462 · Balance 5,088 F1: Pursuant to the Agreement and Plan of Merger, dated as of January 29, 2018, (the "Merger Agreement"), by and among Maple Parent Holdings Corp., a Delaware corporation ("Maple Parent"), DPS and Salt Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of DPS ("Merger Sub"), Merger Sub merged on July 9, 2018 with and into Maple Parent (the "Merger"), with Maple Parent surviving the Merger as a wholly-owned subsidiary of DPS. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Restricted Stock Unit ("RSU") of DPS will be settled in exchange for (i) a number of shares underlying such DPS RSU, and (ii) an amount in cash equal to the number of shares underlying such DPS RSU multiplied by the special cash dividend per share amount. Row 6 · 2018-07-09 · Other · Acquired 7 · Balance 5,095 F4: These shares are restricted stock units acquired with dividend equivalent payments made under the Issuer's dividend reinvestment plan with respect to the shares referenced in row (5) above.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2018-07-09 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2018-07-09 · Exercise / conversion · Disposed 1,685 · Balance 0 F5: Each restricted stock unit represented a contingent right to receive one share of the Issuer's Common Stock and was granted pursuant to the Issuer's Omnibus Stock Incentive Plan of 2009. F6: Pursuant to the Merger Agreement, immediately prior to the effective time, each outstanding RSU vested and was settled in exchange for (i) a number of shares of DPS common stock equal to the number of shares underlying such DPS RSU, and (ii) an amount in cash equal to the number of shares underlying such DPS RSU multiplied by the special cash dividend per share amount. F7: These restricted stock units were to vest on March 2, 2019.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2018-07-09 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2018-07-09 · Exercise / conversion · Disposed 1,796 · Balance 0 F5: Each restricted stock unit represented a contingent right to receive one share of the Issuer's Common Stock and was granted pursuant to the Issuer's Omnibus Stock Incentive Plan of 2009. F6: Pursuant to the Merger Agreement, immediately prior to the effective time, each outstanding RSU vested and was settled in exchange for (i) a number of shares of DPS common stock equal to the number of shares underlying such DPS RSU, and (ii) an amount in cash equal to the number of shares underlying such DPS RSU multiplied by the special cash dividend per share amount. F8: These restricted stock units were to vest on March 4, 2020.
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2018-07-09 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2018-07-09 · Exercise / conversion · Disposed 1,462 · Balance 0 F5: Each restricted stock unit represented a contingent right to receive one share of the Issuer's Common Stock and was granted pursuant to the Issuer's Omnibus Stock Incentive Plan of 2009. F6: Pursuant to the Merger Agreement, immediately prior to the effective time, each outstanding RSU vested and was settled in exchange for (i) a number of shares of DPS common stock equal to the number of shares underlying such DPS RSU, and (ii) an amount in cash equal to the number of shares underlying such DPS RSU multiplied by the special cash dividend per share amount. F9: These restricted stock units were to vest on March 4, 2021.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of January 29, 2018, (the "Merger Agreement"), by and among Maple Parent Holdings Corp., a Delaware corporation ("Maple Parent"), DPS and Salt Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of DPS ("Merger Sub"), Merger Sub merged on July 9, 2018 with and into Maple Parent (the "Merger"), with Maple Parent surviving the Merger as a wholly-owned subsidiary of DPS. Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Restricted Stock Unit ("RSU") of DPS will be settled in exchange for (i) a number of shares underlying such DPS RSU, and (ii) an amount in cash equal to the number of shares underlying such DPS RSU multiplied by the special cash dividend per share amount.

F2: These shares are restricted stock units acquired with dividend equivalent payments made under the Issuer's dividend reinvestment plan with respect to the shares referenced in row (1) above.

F3: These shares are restricted stock units acquired with dividend equivalent payments made under the Issuer's dividend reinvestment plan with respect to the shares referenced in row (3) above.

F4: These shares are restricted stock units acquired with dividend equivalent payments made under the Issuer's dividend reinvestment plan with respect to the shares referenced in row (5) above.

F5: Each restricted stock unit represented a contingent right to receive one share of the Issuer's Common Stock and was granted pursuant to the Issuer's Omnibus Stock Incentive Plan of 2009.

F6: Pursuant to the Merger Agreement, immediately prior to the effective time, each outstanding RSU vested and was settled in exchange for (i) a number of shares of DPS common stock equal to the number of shares underlying such DPS RSU, and (ii) an amount in cash equal to the number of shares underlying such DPS RSU multiplied by the special cash dividend per share amount.

F7: These restricted stock units were to vest on March 2, 2019.

F8: These restricted stock units were to vest on March 4, 2020.

F9: These restricted stock units were to vest on March 4, 2021.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 07, 2026 Filed May 11, 2026 21:10 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionRestricted Stock Unit · Derivative	257	Not disclosed	Not disclosed	Disclosure SEC source: 0000874716-26-000087 · wk-form4_1778533854.xml · derivative · entry 4 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 257 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock that vested in one installment on May 7, 2026. F4 · price: Not applicable. F3 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock that vested in one installment on May 7, 2026. F3 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock that vested in one installment on May 7, 2026. Read SEC document
May 07, 2026 Filed May 11, 2026 21:10 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	257	$0.00	$0.00	Disclosure SEC source: 0000874716-26-000087 · wk-form4_1778533854.xml · nonDerivative · entry 1 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 519 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
August 22, 2025 Filed Aug 26, 2025 21:00 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative	2,187	Not disclosed Strike: $206.62	Not disclosed	Disclosure SEC source: 0000874716-25-000146 · wk-form4_1756242006.xml · derivative · entry 5 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,187 shares Expires 2028-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Not applicable. F4 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vested in one installment on the one year anniversary of the date of grant or on the date of the 2019 annual meeting of shareholders, whichever event was earlier. Read SEC document
August 22, 2025 Filed Aug 26, 2025 21:00 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GiftCommon Stock	259	$0.00	$0.00	Disclosure SEC source: 0000874716-25-000146 · wk-form4_1756242006.xml · nonDerivative · entry 4 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · The O'Hanian-Szostak Family Foundation Disclosed balance after: 259 F3 · ownership.nature: The reporting person is a trustee of The O'Hanian-Szostak Family Foundation ('Foundation') and has power to direct the distribution of assets held by the Foundation. Read SEC document
August 22, 2025 Filed Aug 26, 2025 21:00 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GiftCommon Stock	259	$0.00	$0.00	Disclosure SEC source: 0000874716-25-000146 · wk-form4_1756242006.xml · nonDerivative · entry 3 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Trust of M. Anne Szostak Disclosed balance after: 1,542 F2 · ownership.nature: The reporting person is the settlor of the Trust of M. Anne Szostak ("Trust") and the trustee of the Trust, has power to direct the distribution of Trust assets, and has the power to revoke or amend the Trust. The reporting person has a pecuniary interest in the shares held by the Trust. Read SEC document
August 22, 2025 Filed Aug 26, 2025 21:00 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	2,187	$647.33	$1,415,700.21	Disclosure SEC source: 0000874716-25-000146 · wk-form4_1756242006.xml · nonDerivative · entry 2 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 262 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $647.30 to a high of $647.45 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document
August 22, 2025 Filed Aug 26, 2025 21:00 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	2,187	$206.62	$451,877.94	Disclosure SEC source: 0000874716-25-000146 · wk-form4_1756242006.xml · nonDerivative · entry 1 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,449 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 21, 2025 Filed May 23, 2025 21:00 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative	1,046	Not disclosed Strike: $160.28	Not disclosed	Disclosure SEC source: 0000874716-25-000094 · wk-form4_1748034012.xml · derivative · entry 4 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,046 shares Expires 2027-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vested in one installment on the one year anniversary of the date of grant or on the date of the 2018 annual meeting of shareholders, whichever event was earlier. Read SEC document
May 21, 2025 Filed May 23, 2025 21:00 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	1,260	$512.34	$645,544.75	Disclosure SEC source: 0000874716-25-000094 · wk-form4_1748034012.xml · nonDerivative · entry 3 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Trust of M. Anne Szostak Disclosed balance after: 1,801 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $511.81 to a high of $512.61 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. F2 · ownership.nature: The reporting person is the settlor of the Trust of M. Anne Szostak ("Trust") and the trustee of the Trust, has power to direct the distribution of Trust assets, and has the power to revoke or amend the Trust. The reporting person has a pecuniary interest in the shares held by the Trust. Read SEC document
May 21, 2025 Filed May 23, 2025 21:00 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	1,046	$513.74	$537,372.04	Disclosure SEC source: 0000874716-25-000094 · wk-form4_1748034012.xml · nonDerivative · entry 2 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 262 Read SEC document
May 21, 2025 Filed May 23, 2025 21:00 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	1,046	$160.28	$167,652.88	Disclosure SEC source: 0000874716-25-000094 · wk-form4_1748034012.xml · nonDerivative · entry 1 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,308 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 07, 2025 Filed May 8, 2025 23:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GrantRestricted Stock Unit · Derivative	257	$0.00	$0.00	Disclosure SEC source: 0000874716-25-000082 · wk-form4_1746745291.xml · derivative · entry 5 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 257 Underlying: Common Stock · 257 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2026 annual meeting of shareholders, whichever event earlier. F4 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2026 annual meeting of shareholders, whichever event earlier. F4 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2026 annual meeting of shareholders, whichever event earlier. Read SEC document
May 07, 2025 Filed May 8, 2025 23:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GrantNon-Qualified Stock Option (right-to-buy) · Derivative	600	$0.00 Strike: $486.61	$0.00	Disclosure SEC source: 0000874716-25-000082 · wk-form4_1746745291.xml · derivative · entry 4 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600 Underlying: Common Stock · 600 shares Expires 2035-05-06 F3 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2026 annual meeting of shareholders, whichever event is earlier. Read SEC document
May 06, 2025 Filed May 8, 2025 23:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionRestricted Stock Unit · Derivative	262	$0.00	$0.00	Disclosure SEC source: 0000874716-25-000082 · wk-form4_1746745291.xml · derivative · entry 3 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 262 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event was earlier. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event was earlier. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event was earlier. Read SEC document
May 06, 2025 Filed May 8, 2025 23:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	262	$0.00	$0.00	Disclosure SEC source: 0000874716-25-000082 · wk-form4_1746745291.xml · nonDerivative · entry 1 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 262 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 07, 2025 Filed Feb 10, 2025 22:03 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	3,000	$465.95	$1,397,835.00	Disclosure SEC source: 0000874716-25-000004 · wk-form4_1739224981.xml · nonDerivative · entry 1 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Trust of M. Anne Szostak Disclosed balance after: 3,061 F1 · ownership.nature: The reporting person is the settlor of the Trust of M. Anne Szostak ("Trust") and the trustee of the Trust, has power to direct the distribution of Trust assets, and has the power to revoke or amend the Trust. The reporting person has a pecuniary interest in the shares held by the Trust. Read SEC document
September 06, 2024 Filed Sep 9, 2024 20:18 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	500	$469.37	$234,686.15	Disclosure SEC source: 0000874716-24-000131 · wk-form4_1725913125.xml · nonDerivative · entry 3 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · The O'Hanian-Szostak Family Foundation Disclosed balance after: 0 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $468.98 to a high of $469.55 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. F2 · ownership.nature: The reporting person is a trustee of The O'Hanian-Szostak Family Foundation ('Foundation') and has power to direct the distribution of assets held by the Foundation. Read SEC document
September 05, 2024 Filed Sep 9, 2024 20:18 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GiftCommon Stock	500	$0.00	$0.00	Disclosure SEC source: 0000874716-24-000131 · wk-form4_1725913125.xml · nonDerivative · entry 2 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · The O'Hanian-Szostak Family Foundation Disclosed balance after: 500 F2 · ownership.nature: The reporting person is a trustee of The O'Hanian-Szostak Family Foundation ('Foundation') and has power to direct the distribution of assets held by the Foundation. Read SEC document
September 05, 2024 Filed Sep 9, 2024 20:18 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GiftCommon Stock	500	$0.00	$0.00	Disclosure SEC source: 0000874716-24-000131 · wk-form4_1725913125.xml · nonDerivative · entry 1 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Trust of M. Anne Szostak Disclosed balance after: 6,061 F1 · ownership.nature: The reporting person is the settlor of the Trust of M. Anne Szostak ("Trust") and the trustee of the Trust, has power to direct the distribution of Trust assets, and has the power to revoke or amend the Trust. The reporting person has a pecuniary interest in the shares held by the Trust. Read SEC document
May 08, 2024 Filed May 8, 2024 23:02 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GiftCommon Stock	257	$0.00	$0.00	Disclosure SEC source: 0000874716-24-000104 · wk-form4_1715209347.xml · nonDerivative · entry 3 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Trust of M. Anne Szostak Disclosed balance after: 6,561 F1 · balance_after: Includes 1,604 shares of IDEXX Laboratories, Inc. common stock contributed by the reporting person to the Trust of M. Anne Szostak (as defined in note (2) below). F2 · ownership.nature: The reporting person is the settlor of the Trust of M. Anne Szostak ('Trust') and the trustee of the Trust, has power to direct the distribution of Trust assets, and has the power to revoke or amend the Trust. The reporting person has a pecuniary interest in the shares transferred to the Trust. Read SEC document
May 08, 2024 Filed May 8, 2024 23:02 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GiftCommon Stock	257	$0.00	$0.00	Disclosure SEC source: 0000874716-24-000104 · wk-form4_1715209347.xml · nonDerivative · entry 2 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Read SEC document
May 06, 2024 Filed May 8, 2024 23:02 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionRestricted Stock Unit · Derivative	257	$0.00	$0.00	Disclosure SEC source: 0000874716-24-000104 · wk-form4_1715209347.xml · derivative · entry 6 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 257 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event was earlier. F5 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event was earlier. F5 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event was earlier. Read SEC document
May 06, 2024 Filed May 8, 2024 23:02 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GrantRestricted Stock Unit · Derivative	262	$0.00	$0.00	Disclosure SEC source: 0000874716-24-000104 · wk-form4_1715209347.xml · derivative · entry 5 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 262 Underlying: Common Stock · 262 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier. F4 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier. F4 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier. Read SEC document
May 06, 2024 Filed May 8, 2024 23:02 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GrantNon-Qualified Stock Option (right-to-buy) · Derivative	609	$0.00 Strike: $476.87	$0.00	Disclosure SEC source: 0000874716-24-000104 · wk-form4_1715209347.xml · derivative · entry 4 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 609 Underlying: Common Stock · 609 shares Expires 2034-05-05 F3 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2025 annual meeting of shareholders, whichever event is earlier. Read SEC document
May 06, 2024 Filed May 8, 2024 23:02 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	257	$0.00	$0.00	Disclosure SEC source: 0000874716-24-000104 · wk-form4_1715209347.xml · nonDerivative · entry 1 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 257 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 17, 2023 Filed May 19, 2023 21:03 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GrantRestricted Stock Unit · Derivative	257	Not disclosed	Not disclosed	Disclosure SEC source: 0000874716-23-000082 · wf-form4_168453021084091.xml · derivative · entry 2 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 257 Underlying: Common Stock · 257 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event is earlier. F2 · price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event is earlier. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event is earlier. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event is earlier. Read SEC document
May 17, 2023 Filed May 19, 2023 21:03 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GrantNon-Qualified Stock Option (right-to-buy) · Derivative	645	$0.00 Strike: $487.12	$0.00	Disclosure SEC source: 0000874716-23-000082 · wf-form4_168453021084091.xml · derivative · entry 1 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 645 Underlying: Common Stock · 645 shares Expires 2033-05-16 F1 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2024 annual meeting of shareholders, whichever event is earlier. Read SEC document
May 11, 2023 Filed May 15, 2023 21:32 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionRestricted Stock Unit · Derivative	344	Not disclosed	Not disclosed	Disclosure SEC source: 0000874716-23-000056 · wf-form4_168418632750826.xml · derivative · entry 3 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 344 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event was earlier. F3 · price: Not applicable. F2 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event was earlier. F2 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event was earlier. Read SEC document
May 11, 2023 Filed May 15, 2023 21:32 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	344	$0.00	$0.00	Disclosure SEC source: 0000874716-23-000056 · wf-form4_168418632750826.xml · nonDerivative · entry 1 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,604 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 05, 2023 Filed May 8, 2023 21:03 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	500	$476.12	$238,060.00	Disclosure SEC source: 0000874716-23-000043 · wf-form4_168357980705648.xml · nonDerivative · entry 3 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Trust of M. Anne Szostak Disclosed balance after: 4,700 F4 · price: Represents the weighted average price of the shares sold ranging from a low of $475.84 to a high of $476.31 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. F2 · ownership.nature: The reporting person is the settlor of the Trust of M. Anne Szostak ("Trust") and the trustee of the Trust, has power to direct the distribution of Trust assets, and has the power to revoke or amend the Trust. The reporting person has a pecuniary interest in the shares transferred to the Trust. Read SEC document
May 05, 2023 Filed May 8, 2023 21:03 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	800	$475.27	$380,216.00	Disclosure SEC source: 0000874716-23-000043 · wf-form4_168357980705648.xml · nonDerivative · entry 2 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Trust of M. Anne Szostak Disclosed balance after: 5,200 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $474.67 to a high of $475.66 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. F2 · ownership.nature: The reporting person is the settlor of the Trust of M. Anne Szostak ("Trust") and the trustee of the Trust, has power to direct the distribution of Trust assets, and has the power to revoke or amend the Trust. The reporting person has a pecuniary interest in the shares transferred to the Trust. Read SEC document
May 05, 2023 Filed May 8, 2023 21:03 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	700	$473.59	$331,513.00	Disclosure SEC source: 0000874716-23-000043 · wf-form4_168357980705648.xml · nonDerivative · entry 1 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Trust of M. Anne Szostak Disclosed balance after: 6,000 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $473.17 to a high of $474.13 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. F2 · ownership.nature: The reporting person is the settlor of the Trust of M. Anne Szostak ("Trust") and the trustee of the Trust, has power to direct the distribution of Trust assets, and has the power to revoke or amend the Trust. The reporting person has a pecuniary interest in the shares transferred to the Trust. Read SEC document
February 08, 2023 Filed Feb 10, 2023 22:05 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GiftCommon Stock	5,816	$0.00	$0.00	Disclosure SEC source: 0001567619-23-002399 · doc1.xml · nonDerivative · entry 4 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust of M. Anne Szostak Disclosed balance after: 6,700 F2 · ownership.nature: The reporting person is the settlor of the Trust of M. Anne Szostak ("Trust") and the trustee of the Trust, has power to direct the distribution of Trust assets, and has the power to revoke or amend the Trust. The reporting person has a pecuniary interest in the shares transferred to the Trust. Read SEC document
February 08, 2023 Filed Feb 10, 2023 22:05 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GiftCommon Stock	370	$0.00	$0.00	Disclosure SEC source: 0001567619-23-002399 · doc1.xml · nonDerivative · entry 3 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 2021 Szostak IDEXX GRAT Disclosed balance after: 0 Read SEC document
February 08, 2023 Filed Feb 10, 2023 22:05 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GiftCommon Stock	371	$0.00	$0.00	Disclosure SEC source: 0001567619-23-002399 · doc1.xml · nonDerivative · entry 2 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 2021 Szostak IDEXX GRAT Disclosed balance after: 370 Read SEC document
February 08, 2023 Filed Feb 10, 2023 22:05 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GiftCommon Stock	5,816	$0.00	$0.00	Disclosure SEC source: 0001567619-23-002399 · doc1.xml · nonDerivative · entry 1 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 2021 Szostak IDEXX GRAT Disclosed balance after: 741 F1 · ownership.nature: The reporting person is the settlor and trustee of the 2021 Szostak IDEXX GRAT (the "GRAT"). The GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein. Read SEC document
December 02, 2022 Filed Dec 6, 2022 22:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative	2,000	Not disclosed Strike: $160.28	Not disclosed	Disclosure SEC source: 0001567619-22-021351 · doc1.xml · derivative · entry 5 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,046 Underlying: Common Stock · 2,000 shares Expires 2027-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy 3,046 shares of IDEXX Laboratories, Inc. common stock that vested in one installment on the one year anniversary of the date of grant or on the date of the 2018 annual meeting of shareholders, whichever event was earlier. Read SEC document
December 02, 2022 Filed Dec 6, 2022 22:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	740	$428.55	$317,127.00	Disclosure SEC source: 0001567619-22-021351 · doc1.xml · nonDerivative · entry 2 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,260 Read SEC document
December 02, 2022 Filed Dec 6, 2022 22:01 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	2,000	$160.28	$320,560.00	Disclosure SEC source: 0001567619-22-021351 · doc1.xml · nonDerivative · entry 1 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 11, 2022 Filed May 13, 2022 21:58 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionRestricted Stock Unit · Derivative	224	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-22-010579 · doc1.xml · derivative · entry 6 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344 Underlying: Common Stock · 224 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event was earlier. F6 · price: Not applicable. F5 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event was earlier. F5 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These restricted stock units vested in in one installment on the one year anniversary of the date of grant or on the date of the 2022 annual meeting of shareholders, whichever event was earlier. Read SEC document
May 11, 2022 Filed May 13, 2022 21:58 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GrantRestricted Stock Unit · Derivative	344	Not disclosed	Not disclosed	Disclosure SEC source: 0001567619-22-010579 · doc1.xml · derivative · entry 5 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 568 Underlying: Common Stock · 344 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event is earlier. F6 · price: Not applicable. F4 · derivative.exercise_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event is earlier. F4 · derivative.expiration_date: Each restricted stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. Restricted stock units vest in in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event is earlier. Read SEC document
May 11, 2022 Filed May 13, 2022 21:58 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GrantNon-Qualified Stock Option (right-to-buy) · Derivative	945	Not disclosed Strike: $333.90	Not disclosed	Disclosure SEC source: 0001567619-22-010579 · doc1.xml · derivative · entry 4 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 945 Underlying: Common Stock · 945 shares Expires 2032-05-10 F6 · price: Not applicable. F3 · derivative.exercise_date: Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2023 annual meeting of shareholders, whichever event is earlier. Read SEC document
May 11, 2022 Filed May 13, 2022 21:58 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	Exercise / conversionCommon Stock	224	$0.00	$0.00	Disclosure SEC source: 0001567619-22-010579 · doc1.xml · nonDerivative · entry 1 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 06, 2022 Filed May 10, 2022 09:26 UTC	TUPPERWARE BRANDS CORP TUP · Entity 90566	GrantCommon Stock	15,106	$9.93	$150,002.58	Disclosure SEC source: 0001127602-22-013885 · form4.xml · nonDerivative · entry 1 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,858 F1 · shares: Restricted Stock Unit award that vests on the Issuer's next Annual Meeting of Shareholders, currently planned for May 5, 2023, at which time the units convert into Tupperware Brands' Corporation common stock on a one-for-one basis. Read SEC document
February 07, 2022 Filed Feb 9, 2022 22:00 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GiftCommon Stock	660	$0.00	$0.00	Disclosure SEC source: 0001567619-22-003061 · doc1.xml · nonDerivative · entry 2 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust of M. Anne Szostak Disclosed balance after: 660 F2 · ownership.nature: The reporting person is the settlor of the Trust of M. Anne Szostak ("Trust") and the trustee of the Trust, has power to direct the distribution of Trust assets, and has the power to revoke or amend the Trust. The reporting person has a pecuniary interest in the shares transferred to the Trust. Read SEC document
February 07, 2022 Filed Feb 9, 2022 22:00 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	GiftCommon Stock	660	$0.00	$0.00	Disclosure SEC source: 0001567619-22-003061 · doc1.xml · nonDerivative · entry 1 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 2021 Szostak IDEXX GRAT Disclosed balance after: 6,557 F1 · ownership.nature: The reporting person is the settlor and trustee of the 2021 Szostak IDEXX GRAT (the "GRAT"). The GRAT is irrevocable, and the reporting person disclaims beneficial ownership of these shares except to the extent of her pecuniary interest therein. Read SEC document
August 06, 2021 Filed Aug 9, 2021 21:02 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	5	$694.62	$3,473.10	Disclosure SEC source: 0001567619-21-014772 · doc1.xml · nonDerivative · entry 10 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 2021 Szostak IDEXX GRAT Disclosed balance after: 7,217 Read SEC document
August 06, 2021 Filed Aug 9, 2021 21:02 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	595	$693.91	$412,875.44	Disclosure SEC source: 0001567619-21-014772 · doc1.xml · nonDerivative · entry 9 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 2021 Szostak IDEXX GRAT Disclosed balance after: 7,222 F10 · price: Represents the weighted average price of the shares sold ranging from a low of $693.53 to a high of $694.51 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document
August 06, 2021 Filed Aug 9, 2021 21:02 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	300	$691.75	$207,523.65	Disclosure SEC source: 0001567619-21-014772 · doc1.xml · nonDerivative · entry 8 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 2021 Szostak IDEXX GRAT Disclosed balance after: 7,817 F9 · price: Represents the weighted average price of the shares sold ranging from a low of $691.47 to a high of $692.22 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document
August 06, 2021 Filed Aug 9, 2021 21:02 UTC	IDEXX LABORATORIES INC /DE IDXX · Entity 3057	SaleCommon Stock	300	$690.65	$207,194.70	Disclosure SEC source: 0001567619-21-014772 · doc1.xml · nonDerivative · entry 7 SZOSTAK M ANNE · CIK 0001094176 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · 2021 Szostak IDEXX GRAT Disclosed balance after: 8,117 F8 · price: Represents the weighted average price of the shares sold ranging from a low of $690.32 to a high of $691.21 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.